Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and poor prognosis. Emerging evidence suggests that epigenetic alterations play a crucial role in HCC, suggesting epigenetic inhibition as a promising therapeutic approach. Indeed, the bromodomain and extra-terminal (BET) inhibitors inhibit the proliferation and invasion of various cancers but still lack a strong mechanistic rationale. Here, we identified the differentially expressed mRNAs (DEmRNAs) and lncRNAs (DElncRNAs) in human HCC cell line HepG2 treated with the BET inhibitors, JQ1, OTX015, or ABBV-075. We analyzed the correlation between DEmRNAs and DElncRNAs in common for the three inhibitors based on their expression profiles and performed functional annotation pathway enrichment analysis. Most of these shared DEmRNAs and DElncRNAs, including some novel transcripts, were downregulated, indicating decreased proliferation/adhesion and increased apoptosis/inflammation. Our study suggests that BET proteins play a crucial role in regulating cancer progression-related genes and provide a valuable resource for novel putative biomarkers and therapeutic targets in HCC.

Introduction

Hepatocellular carcinoma (HCC) is the most common primary liver cancer [1]. Chronic liver disease and cirrhosis are the most important risk factors for developing HCC. Emerging evidence suggests that the accumulation of genetic and epigenetic aberrations is associated with the initiation and progression of HCC. The multi-targeted tyrosine kinase inhibitor sorafenib is currently being used as the first-line treatment for HCC [2–4].

The bromodomain and extra-terminal (BET) family of epigenetic reader proteins is comprised of bromodomain-containing protein 2 (BRD2), BRD3, BRD4 and BRDT that bind to acetylated residues on histones and transcription factors in the enhancer or promoter region of genes [5]. BET family proteins regulate the expression of oncogenes and have become
potential therapeutic targets for cancer [6, 7]. Indeed, BET inhibitors, such as JQ1, OTX015, I-BET151, and ABBV-075 inhibit the proliferation and invasion of a range of cancers [8]. JQ1 has been extensively studied as the first identified BET inhibitor, and JQ1 treatment significantly reduces cell proliferation and induces apoptosis in several cancer types. In the case of HCC, JQ1 suppresses HCC tumorigenesis by reducing the expression of active-enhancer-related genes such as the oncogene c-MYC and the cell cycle regulatory molecule E2F2 [9–11]. OTX015 was the first BET inhibitor to be tested in a clinical trial. It exhibited antitumor activity against leukemia, lymphoma, nuclear protein in testis (NUT) carcinoma, and other solid cancers [12–14]. ABBV-075, a recently developed oral pan-BET inhibitor, has been reported to induce apoptosis and tumor regression in several hematological and solid cancer types [15].

Long non-coding RNAs (lncRNAs) are RNA transcripts longer than 200 nucleotides that are not translated into proteins [16]. They play crucial roles in gene regulation, including chromatin remodeling, transcription, and post-transcriptional regulation [17]. Importantly, lncRNAs are emerging as key regulators of cancer signaling [18]; they are aberrantly expressed in various cancers and play critical roles in tumor initiation, progression, and metastasis, suggesting clinical potential as biomarkers and therapeutic targets [19–21]. To date, a total of 74 lncRNAs have been reported to be involved in HCC, including HULC [22], ATB [23], HOTAIR [24], ZEB1-AS1 [25], and HOTTIP [26], the expression of which is deregulated in HCC [27].

HCC-associated lncRNAs are significantly associated with tumor clinicopathological and metastatic features and can have either oncogenic or tumor-suppressive properties. They also affect several cancer phenotypes by altering miRNA and mRNA expression and stability [27, 28].

The present study performed a comprehensive analysis of mRNA and lncRNAs expression profiles of BET inhibitor-treated human HCC cell line HepG2 using RNA sequencing (RNA-Seq). We identified differentially expressed mRNAs (DEmRNAs) and lncRNAs (DElncRNAs) and analyzed the correlation between DEmRNAs and DElncRNAs. By focusing on the transcripts commonly up- and downregulated by JQ1, OTX015, and ABBV-075, we identified potentially significant transcripts for HCC progression, including some novel DEmRNAs and DElncRNAs.

Materials and methods

Cell culture and treatment

HCC cell lines HepG2 and Huh7 were purchased from Korean Cell Line Bank (Seoul, Korea). The cells were cultured in MEM containing 10% heat-inactivated FBS, penicillin, and streptomycin (Thermo Fisher Scientific, Waltham, MA, USA). They were maintained at 37°C in a humidified atmosphere with 95% air/5% CO₂. The BET inhibitors, JQ1, OTX015, and ABBV-075, were purchased from Tocris Bioscience (Minneapolis, MN, USA). They were dissolved in dimethyl sulfoxide (DMSO) at a stock concentration of 10 mM and stored at -20°C. The cells were treated with various concentrations (50 nM, 500 nM, and 5 μM) of JQ1, OTX015, and ABBV-075 for different durations (12 h and 24 h).

Cell viability assay

Cell viability was examined using a PreMix water-soluble tetrazolium-1 (WST-1) cell proliferation assay kit (Takara, Shiga, Japan). The HepG2 cells were seeded at a density of 5 x 10³ per well in 96-well plates and treated with JQ1, OTX015, or ABBV-075 for 0 to 24 h. Thereafter, PreMix WST-1 was added to each well and the incubation was continued at 37°C for another 4 h. Absorbance was measured using a microplate reader at 450 nm. The data represent three independent experiments (n = 3).
RNA library preparation and RNA-seq

Total RNA was extracted from 4 groups (12 independent samples) samples. Experimental triplicates of HepG2 cells were treated with DMSO (3 samples), 5 μM JQ1 (3 samples), or 5 μM OTX015 (3 samples) for 24 h or with 50 nM ABBV-075 (3 samples) for 12 h. The RNA library was created as previously described [29]. Briefly, total RNA was extracted using RNAiso Plus (Takara, Shiga, Japan) and the RNeasy Mini Kit (QIAGEN Inc., Hilden, Germany) according to the manufacturer’s instructions. Ribosomal RNA (rRNA) was depleted using RiboMinus Eukaryote kit (Invitrogen, Carlsbad, CA, USA). RNA libraries were created using the NEBNext Ultra Directional RNA Library Preparation Kit for Illumina (New England BioLabs, Ipswich, MA, USA). Transcriptome sequencing was performed using the Illumina HiSeq2500 platform (Macrogen, Seoul, Korea).

Differentially expressed mRNAs and lncRNAs analysis

The DEmRNAs and DElncRNAs were analyzed following a previously reported pipeline [30]. Briefly, the FASTQC file was checked for quality control, and adapters and low-quality bases were removed using Trimmomatic [31]. The FASTQ files were aligned to the Homo sapiens reference sequence GRCh38 using STAR (version 2.7.1) software [32]. DESeq2 [33] was used with the default parameters to obtain DEmRNAs and DElncRNAs. DESeq2 used the median method to normalize sequencing depth and RNA composition. Fold change in expression ≥ 1.5 log₂ and adjusted p-value (padj) ≤ 0.05 were used as the criteria to define DEmRNAs and DElncRNAs. The RNA-seq data were deposited in the Gene Expression Omnibus database under dataset accession numbers GSE158552 and GSE189376.

Correlation analysis

The Pearson correlation coefficient (PCC) and R value were calculated to assess the similarity of the gene expression profiles. Then the correlation coefficients between DEmRNAs and DElncRNAs were weighted by a power function. We selected the PCC greater than 0.8 as the meaningful value.

Functional annotation and canonical pathway analysis

Database for Annotation, Visualization, and Integrated Discovery (DAVID version 6.8, http://david.abcc.ncifcrf.gov/home.jsp) was used to determine functions most significantly enriched in the genes in the datasets [34]. DAVID uses a modified Fisher’s exact p-value to examine gene ontology (GO) enrichment. A p-value ≤ 0.05 was used as the criterion for GO term analysis. Values less than 0.05 are considered to indicate enrichment in the annotation category. KEGG Orthology-Based Annotation System (KOBAS version 3.0, http://kobas.cbi.pku.edu.cn/) was used to analyze the annotation and identification of enriched KEGG pathways [35]. All DEmRNAs were subjected to Gene-list Enrichment analysis under default conditions. Enriched p-value ≤ 0.05 was used as the criterion for KOBAS. Genomic Regions Enrichment of Annotations Tool (GREAT) was used for functional annotation analysis of DElncRNAs [36]. GREAT analyzes the annotations of nearby genes to assign biological associations to sets of non-coding genomic regions. GREAT analysis was performed by submitting the chromosomal locations of differentially expressed DElncRNAs to the website http://bejerano.stanford.edu/great/public/html/. A p-value ≤ 0.05 was used as the criterion for GREAT analysis. Gene Set Enrichment Analysis (GSEA) software (http://www.broad.mit.edu/gsea/msigdb/) was used to analyze the biological processes of statistically significant gene sets [37]. All DEmRNAs with normalized counts were submitted to the GSEA and analyzed with gene symbol annotation in
default conditions. GSEA calculated a normalized enrichment score (NES) for the expression level of each gene set. A \( p \)-value \( \leq 0.05 \) was used as the criterion for GSEA. Each of these genes was mapped to objects by Ingenuity Pathway Analysis [38] (IPA; QIAGEN Inc., Hilden, Germany, https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis). IPA software conducts functional analysis to show genes involved in biological functions and disease.

**Total RNA extraction and quantitative RT-PCR**

Total RNA extractions and cDNA sample preparation were performed using Takara’s kits according to the manufacturer’s instruction (Takara, Shiga, Japan). Quantitative reverse transcription PCR (qRT-PCR) was performed using an ABI 7500 real-time PCR system (Applied Biosystems Inc., Foster City, CA, USA). The critical threshold (\( \Delta \)CT) values were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression for mRNAs and U6 for lncRNAs, which served as an internal control. The results were also analyzed using the comparative critical threshold (\( \Delta \Delta \)CT) method. Specific primers were designed using Primer Bank (http://pga.mgh.harvard.edu/primerbank/index.html). The primers for qRT-PCR are listed in the S1 Table.

**Statistical analyses**

The statistical analyses were performed using IBM SPSS Statistics ver. 26.0 (IBM Corporation, Armonk, NY, USA). All data are expressed as the mean \( \pm \) standard deviation (SD). All qRT-PCR data were tested using one-way ANOVA followed by Tukey’s honestly significant difference (HSD) post hoc test. Differences for which \( p < 0.05 \) were considered significant.

**Results**

**Effects of BET inhibitor on HCC cell line HepG2**

The flowchart for the comprehensive analysis of DEmRNAs and DElncRNAs is shown in Fig 1. We first determined the optimal experimental conditions for transcriptional profiling. We have previously shown with EdU incorporation assays that BET inhibitors reduce HepG2 cell proliferation [39]. We now examined their effects on cell viability at various concentrations (50 nM, 500 nM, and 5 \( \mu \)M) and time points (12 h and 24 h). JQ1, OTX015, and ABBV-075 significantly reduced cell proliferation in a dose-dependent manner after 12 h and 24 h (S1 Fig). However, ABBV-075 was effective earlier and at a lower concentration than the other two inhibitors for a given degree of inhibition. For the gene expression profiling, the HepG2 cells were therefore treated with 5 \( \mu \)M of JQ1 or OTX015 for 24 h, but with 50 nM of ABBV-075 for 12 h.

**Identification of differentially expressed mRNAs (DEmRNAs) and lncRNAs (DElncRNAs) in BET inhibitor-treated HepG2 cells**

Following cDNA library construction and RNA sequencing (RNA-seq), the DEmRNAs (Fig 2A) and DElncRNAs (Fig 2B) were selected with a cutoff of log2 fold change \( \geq 1.5 \), log2 fold change \( \leq -1.5 \), and \( p_{adj} \leq 0.05 \). In the JQ1-treated HepG2 cells, a total of 632 DEmRNAs (including 144 upregulated and 488 downregulated) and 105 DElncRNAs (including 34 upregulated and 71 downregulated) were identified. In the OTX015-treated HepG2 cells, a total of 551 DEmRNAs (including 139 upregulated and 412 downregulated) and 94 DElncRNAs (including 25 upregulated and 69 downregulated) were identified. In the ABBV-075-treated HepG2 cells, 793 DEmRNAs (including 188 upregulated and 605 downregulated) and 116 DElncRNAs (including 36 upregulated and 80 downregulated) were identified. For all BET
inhibitor-treated cells, the up- and downregulated DEmRNAs and DElncRNAs are listed in S2–S7 Tables, respectively. 382 DEmRNAs and 60 DElncRNAs were common for all three inhibitors (S8 and S9 Tables, respectively). The top 50 up- and downregulated DEmRNAs and DElncRNAs are shown as heat maps in Fig 2.

The expression profiles of DEmRNAs and DElncRNAs in HepG2 cells treated with JQ1 or OTX015 for 24 h, or with ABBV-075 for 12 h. The Table displays the number of up- and downregulated DEmRNAs (A) and DElncRNAs (B) of BET inhibitor-treated HepG2 cells. The Venn diagrams show the numbers of overlapping up- and downregulated DEmRNAs (A) and DElncRNAs (B). The heat maps represent the top 50 up- and downregulated DEmRNAs (A) and DElncRNAs (B) (log₂ fold change ≥ 1.5, log₂ fold change ≤ -1.5, and padj ≤ 0.05). The color scales represent the log₂ fold change values. Red cells indicate upregulated genes, blue cells indicate downregulated genes. Each experiment was performed in experimental triplicates (n = 3) for each condition, and the results were individually combined. In the BET inhibitor-treated HepG2 cells, 382 DEmRNAs and 60 DElncRNAs were identified in common.

**Functional annotation and pathway enrichment analysis of commonly expressed DEmRNAs and DElncRNAs treated with BET inhibitors**

We performed GO and KEGG pathway analysis to explore the functional classification and pathway enrichment of DEmRNAs and DElncRNAs commonly up- and downregulated in response to BET inhibitor treatment. GO term analysis categorized the results into the
biological process (BP), cellular component (CC), and molecular function (MF) (Fig 3A). Functional annotation analysis of DEmRNAs using DAVID revealed that the most enriched GO terms in the BP category were mainly associated with redox processes, cell adhesion, transmembrane transport, lipid metabolism, and metabolic processes. In CC categories, the DEmRNAs were most enriched in extracellular exosome, extracellular region, an integral component of the plasma membrane, and cytoskeleton. In MF categories, the most significant terms were related to receptor binding, oxidoreductase activity, cytokine activity, transporter activity, and hormone activity. The KEGG pathway analysis for up- and downregulated genes was performed using KOBAS 3.0. The KEGG pathway results (Fig 3B) found primary bile acid biosynthesis, phenylalanine metabolism, taurine, and hypotaurine metabolism, tyrosine metabolism, and maturity-onset diabetes of the young, suggesting that most enriched KEGG pathways were mainly involved in metabolic pathways. We also performed GSEA of DEmRNAs commonly up- and downregulated in response to BET inhibitor treatment (S2A Fig). The degree of enrichment gene sets is shown as a normalized enrichment score (NES). Positive and negative NES values indicate enrichment at the top and bottom of the ranked gene set, respectively. The GSEA approach gave similar results as the GO analysis using DAVID, and the most enriched GO terms were mainly related to metabolic processes. Functional annotation analysis of DElncRNAs using GREAT revealed that DElncRNAs were located near the transcriptional start site, suggesting that the identified DElncRNAs could regulate protein-coding genes (S3A–S3C Fig). We also found that DElncRNAs regulated by the three BET inhibitors are...
enriched in a number of positive and negative biological processes, metabolic processes, and signaling pathways (S3D Fig).

### Functional annotation and pathway enrichment analysis of DEmRNAs of each BET inhibitor treatment

GO term and KEGG pathway analyses were performed to functionally annotate the genes that were commonly up- and downregulated in each BET inhibitor treatment. The GO analysis revealed that the corresponding BP categories were enriched in negative regulation of cell growth, oxidation-reduction process, cellular response of heparin, and autophagic cell death (S4A–S4C Fig, upper panels). The downregulated DEmRNAs were related to biological processes such as cell adhesion, transmembrane transport, drug response, angiogenesis, and metabolism. The top 4 enriched pathways of the KEGG results are shown in the middle panels of S4 Fig. The KEGG pathway analysis revealed that the upregulated DEmRNAs were significantly enriched in ABC transporters, axon guidance, and parathyroid hormone synthesis, secretion, and action. In contrast, the downregulated DEmRNAs were enriched in metabolic pathways, PI3K-Akt signaling pathway, drug metabolism—cytochrome P450, and bile secretion. Thus, after treatment with different BET inhibitors, the commonly up- and downregulated genes were highly enriched in metabolic processes and pathways. We also performed GSEA of DEmRNAs (bottom panel of S4 Fig) and obtained similar results as in the GO analysis using DAVID, i.e., the DEmRNAs in each BET-inhibitor-treated group were positively

---

**Fig 3. Functional annotation and pathway enrichment analysis of commonly expressed DEmRNAs treated with BET inhibitors.**

(A) GO term analysis of commonly expressed DEmRNAs. The numbers of genes enriched for each term are displayed for the top 5 GO terms in biological process (BP; upper panel), cellular component (CC; middle panel), and molecular function (MF; bottom panel). Each row represents an enriched function, and the length of the bar represents the enrichment ratio, which is calculated as input gene number/background gene number (KOBAS, http://kobas.cbi.pku.edu.cn). In the KOBAS algorithm, clusters are divided according to the values calculated for the enriched terms. The colors of the bars represent different clusters and show the top 5 with the highest enrichment ratios.

(B) KEGG pathway enrichment analysis of commonly expressed DEmRNAs. Each row represents an enriched function, and the length of the bar represents the enrichment ratio, which is calculated as input gene number/ background gene number (KOBAS, http://kobas.cbi.pku.edu.cn). In the KOBAS algorithm, clusters are divided according to the values calculated for the enriched terms. The colors of the bars represent different clusters and show the top 5 with the highest enrichment ratios.

https://doi.org/10.1371/journal.pone.0266966.g003
correlated with metabolic processes. DEmRNAs in the JQ1-treated group were negatively correlated with genes involved in the regulation of catalytic activity, and the groups treated with OTX015 and ABBV-075 were negatively correlated with genes involved in the cellular response to stress and binding of protein-containing complexes, respectively.

Analysis of correlations between DElncRNAs and DEmRNAs

Pearson correlation analysis identified 22,950 DElncRNA-DEmRNA pairs ($|r| \geq 0.7, p\text{-value} \leq 0.05$), which included 382 DEmRNAs and 60 DElncRNAs common to all BET-treated cells. The Pearson correlation coefficient (PCC) values were visualized by a heat map (Fig 4A). Based on the DElncRNAs and correlated DEmRNAs expression patterns, the nodes and correlations were divided into two main Modules. Among the positively correlated DElncRNA-DEmRNA pairs, the large and small segments were defined as Modules 1 and 2, respectively. Interestingly, the expression of both DEmRNAs and DElncRNAs were downregulated in Module 1, while in Module 2 they were both upregulated. The top 5 DElncRNA-DEmRNA pairs with positive correlation coefficients $> 0.985$ are shown in Fig 4B. The PCC

![Figure 4](https://doi.org/10.1371/journal.pone.0266966.g004)
values of the DElncRNA-DEmRNA pairs in Modules1 and 2 are listed in the S10 and S11 Tables, respectively.

**Analysis of Module 1—Functional annotation and pathway enrichment analysis**

Based on the results of correlation analysis, we performed functional annotation of the DEmRNAs of Module 1. The top 5 GO terms of the BP, CC, and MF are shown in Fig 4C. In the BP categories, most enriched GO terms were related to cell adhesion, transmembrane transport, metabolic process, angiogenesis, and response to drugs, similar for each BET inhibitor treatment. In the CC categories, the DEmRNAs were most enriched in integral components of membrane and plasma membrane. In the MF categories, the most significant terms were related to receptor binding, cytokine activity, oxidoreductase activity, transporter activity, and hormone activity. The KEGG pathway results showed phenylalanine metabolism, primary bile acid biosynthesis, taurine and hypotaurine metabolism, and tyrosine metabolism, suggesting that the most enriched KEGG pathways were mainly involved in metabolic pathways. We also performed GSEA of DEmRNAs of Module 1 (S2B Fig). This approach yielded similar results as the GO analysis using DAVID, i.e. the most enriched GO terms were mainly involved in metabolic processes.

**Analysis of Module 1—Biofunctional analysis**

To further understand the molecular functions of the genes, we conducted biofunctional analysis using Ingenuity Pathway Analysis (IPA). Activation Z-scores were used to predict whether biological functions are activated or inhibited after treatment with BET inhibitors. Most of the biofunctional results showed inhibition, including the size of the body, transport of molecules, activation of cells, cellular homeostasis, and survival of an organism. In contrast, several biofunctions were activated, including apoptosis, glucose metabolism disorder, and inflammation of organs (Fig 5A). IPA downstream effects analysis identifies biological processes and functions related to the size of the body and predicts whether these processes increase or decrease (Fig 5B). Of the genes related to the size of the body, only the top 10 genes related to cellular growth and proliferation are listed in Fig 5C. To validate the RNA-seq results, we confirmed the expression of the DEmRNAs and DElncRNAs by qRT-PCR (Fig 5D). Several DEmRNAs and DElncRNAs related to the size of the body and its functions were selected and validated.

The apoptosis-related genes of the IPA downstream effect analysis are shown in Fig 6A. Of the genes related to apoptosis, only the top 10 genes related to cell death and survival are listed in Fig 6B. The selected DEmRNAs and DElncRNAs related to apoptosis were validated using qRT-PCR (Fig 6C).

The inflammation of organ-related genes of the IPA downstream effect analysis is shown in Fig 7A. Of the genes related to the inflammation of the organ, only the top 10 genes related to apoptosis are listed in Fig 7B. The selected DEmRNAs and DElncRNAs related to the inflammation of organs were validated using qRT-PCR (Fig 7C).

The adhesion of tumor cell lines-related genes of the IPA downstream effect analysis is shown in Fig 8A. Of the genes related to the adhesion of tumor cell lines, only the top 10 genes related to metastasis are listed in Fig 8B. The selected DEmRNAs and DElncRNAs related to the adhesion of tumor cell lines were validated using qRT-PCR (Fig 8C).

Taken together, we found that most of the DEmRNAs and DElncRNAs commonly found in JQ1, OTX015, and ABBV-075 treatments were downregulated, resulting in decreased proliferation and adhesion and increased apoptosis and inflammation. These data strongly suggest
that BET inhibitors highly selectively suppress the expression of mRNAs and lncRNAs involved in HCC development and progression.

Analysis of Module 2—Functional annotation and pathway enrichment analysis

Based on the results of the correlation analysis, we performed functional annotation of DEmRNAs of Module 2. The top 5 GO terms of the BP, CC, and MF are shown in Fig 9A. In the BP categories, most enriched GO terms were mainly related to the oxidation-reduction process, cellular response to heparin, and cell migration involving in sprouting angiogenesis. There were no significant results in the CC category. In the MF categories, the only significant term was related to GTPase inhibitor activity. The KEGG pathway results showed sulfur metabolism, primary bile acid biosynthesis, and glycosaminoglycan degradation, suggesting that the most enriched KEGG pathways were mainly involved in metabolic pathways. We also performed GSEA of DEmRNAs of Module 2 (S2C Fig). The GSEA results showed that DEmRNAs of Module 2 were negatively correlated with genes involved in the homeostatic process. The
The selected DEmRNAs and DElncRNAs were validated using qRT-PCR (Fig 9D). As shown by RNA-seq, the selected DEmRNAs and DElncRNAs were upregulated by the BET inhibitors. In addition, we further validated a novel putative biomarker in the human HCC cell line Huh7. Huh7 cells were treated with BET inhibitors under the same conditions as HepG2. The DEmRNAs and DElncRNAs were validated using qRT-PCR. The expressions of DEmRNAs (S5 Fig) and DElncRNAs (S6 Fig) involved in HCC progression, apoptosis, and inflammation were consistent with the results of HepG2.

Discussion

Epigenetic inhibition with BET inhibitors is emerging as a therapy for a broad range of cancers, including HCC [2, 3]. Here, we conducted a genome-wide analysis of the transcriptome profiling of BET inhibitor-treated HepG2 cells.
changes potentially underlying by treating the human HCC cell lines HepG2 and Huh7 with the BET inhibitors JQ1, OTX015, or ABBV-075 the inhibition of HCC progression. Selected DEmRNAs and DElncRNAs identified in this study are highlighted below.

JQ1 and OTX015 are known to inhibit the expression of active enhancer-associated genes, c-MYC oncogene, MYCN transcription factor, and its target genes involved in HCC progression and tumorigenesis [10, 40]. These BET inhibitors also inhibit HCC cell proliferation and migration in vitro [39]. In that study, JQ1 and OTX015 selectively inhibited the expression of cell migration-related genes such as ASIC1, CD9, SST5, and VAV3 through SMARCA4. In line with this, we showed here that the BET inhibitors reduced the expression of proliferation- or migration-related genes such as AREG, CD9, EREG, and VAV3. VAV3 (Vav guanine nucleotide exchange factor 3) counteracts apoptosis and is overexpressed in various cancers [41, 42]. ABBV-075 showed anti-apoptotic activity in small-cell lung cancer [43] and non-Hodgkin lymphoma cell lines [44], at least in the latter with a more significant effect than OTX015.

Fig 7. Biofunctional analysis of DEmRNAs related to inflammation of the organ. (A) IPA downstream effects analysis showing the mapping of most significant genes related to organ inflammation from the results of the biofunctional analysis in Module 1. Of the genes related to inflammation of organ, only apoptosis-related genes are shown in bold and red. (B) Log2 fold changes and padj in the expression of genes related to inflammation of the organ. (C) Expression levels of inflammation-related mRNAs and IncRNAs were analyzed by qRT-PCR and normalized to GAPDH or U6 transcript levels, respectively. Overall, the inflammation of organ-related mRNAs and IncRNAs was inhibited by BET inhibitors. The data represent three independent experiments. The values are the mean ± SD of triplicate experiments (⁎⁎p < 0.01).

https://doi.org/10.1371/journal.pone.0266966.g007
Similarly, ABBV-075 was more efficacious than OTX015 in the HepG2 cells. However, the expression levels in the Huh7 cells were not significantly different between each group. OTX015 remains of interest since it showed anticancer effects in many studies and is currently in clinical trials.

The present study also identified cancer-relevant DEmRNAs that have not previously been associated with HCC. Amongst the novel DEmRNAs that JQ1, OTX015, and ABBV-075 commonly downregulated are transcripts such as ADGPR3, GPAM, GPD1, OSBP2, PSMB8, SLC6A9, and SLC30A10. The expression of GPAM (glycerol-3-phosphate acyltransferase), a key enzyme in lipid biosynthesis, is increased in breast and other cancers and highly correlated with clinicopathological parameters [45]; its inhibition reduces ovarian cancer cell migration and the growth of tumor xenograft mouse models [46]. A high expression of GPD1 (glycerol-3-phosphate dehydrogenase 1) has been observed in glioblastoma and glioma and correlates with poor survival in renal cell carcinoma [47]. The expression of PSMB8 (proteasome subunit beta type 8), a component of the 20S proteolytic core particle, is generally increased in tumor cell lines and correlated with poor prognosis [48]; its reduction inhibits the progression and invasion of gastric cancer and glioblastoma [49].
We also found that DEmRNAs involved in cancer growth and progression were upregulated by the three BET inhibitors. For example, \textit{HEXIM1} has previously been described as a pharmacodynamic marker in BET treatments [50]. Noteworthy novel DEmRNAs are \textit{CNNM4} and \textit{USP53}. \textit{CNNM4} is a member of the cyclin and cystathionine \(\beta\)-synthase (CBS) domain divalent metal cation transport mediator family and promotes tumor progression by regulating Mg\(^{2+}\) efflux; its level is inversely correlated with malignancy in colon cancer [51]. \textit{USP53} (Ubiquitin specific peptidase 53) inhibits the initiation and progression of renal cell carcinoma by inhibiting activation of the nuclear factor \(\kappa B\) (NF-\(\kappa B\)) pathway; it promotes apoptosis and inhibits glycolysis in lung adenocarcinoma through FKBP51-AKT1 signaling [52, 53].

Recent evidence suggests that lncRNAs are key modulators of HCC by regulating tumor suppressor genes or oncogenes [22–26, 54]. Here, we found 60 DElncRNAs in BET inhibitor-treated HepG2 cells. Some of the downregulated DElncRNAs have previously been associated with HCC. For example, \textit{HAGLR}, \textit{HNF1A-AS1}, and \textit{PART1} are known to be upregulated in HCC and to promote HCC proliferation and migration [55–57], while the downregulation of \textit{LINC00261} is inconsistent with a previous study [58]. Some of the downregulated DElncRNAs...
that our study newly associates with HCC have been related to other cancers and pathologies. Thus, LINC00242 and LINC02535 affect the proliferation and apoptosis of gastric cancer [59, 60], PRR7-AS1 is involved in colorectal cancer metabolism [61], and LINC01146 and MIR3142HG in inflammation [62, 63]. Noteworthy upregulated novel DElncRNAs in the BET inhibitor-treated HepG2 cells include CCNT2-AS1, CHKBDT, CPB2-AS1, and LINC00910. Of these, CCNT2-AS1 has a prognostic value in renal cell carcinoma [64], and CHKBDT, also known as CHKBDASI, has been negatively correlated with esophageal squamous cell carcinoma [65]. In this study, DElncRNAs and DEmRNAs were paired with the absolute value of the Pearson correlation coefficient. Further studies will be needed to demonstrate the function of novel DElncRNAs in HCC, their interactions with target genes, and the specific lncRNA–mRNA pairs involved in HCC progression.

Several BET inhibitors, including ABBV-075, CPI-0610, GSK525762, and OTX015, are currently in phase 1 or 2 clinical trials [13, 15]. However, the pan-BET inhibitors, especially the oldest such as JQ1, have limited clinical applications due to their toxicity, side effects, and short clinical response [66]. Recently, selective inhibitors targeting BD1 and BD2 have been developed. The BD1 inhibitor, GSK078, showed efficacy in cancer models comparable to the pan-BET inhibitor. The BD2 inhibitors, GSK046 and ABBV-744, were predominantly effective in inflammatory and autoimmune disease models [67, 68]. The present study will inform future efforts to optimize further the development and application of the different BET inhibitors for the treatment of HCC.

Conclusions

We performed a comprehensive analysis of DEmRNAs and DElncRNAs expression profiles and their functional annotation in the BET inhibitor-treated human HCC cell line HepG2. We identified 382 DEmRNAs and 60 DElncRNAs in common for the BET inhibitors, JQ1, OTX015, and ABBV-075, and analyzed the correlation between DEmRNAs and DElncRNAs based on their expression profiles. Additionally, we found novel transcripts involved in proliferation and apoptosis that are commonly reduced by the three inhibitors. Novel DEmRNAs are ADGPR3, GPAM, GPD1, OSBP2, PSMB8, SLC6A9, SLC30A10, and novel DElncRNAs are LINC00242, LINC01146, LINC02535, MIR3142HG, and PRR7-AS1. Our study suggests that alterations at the level of epigenetic components may modulate HCC progression, providing biomarkers for therapeutic targeting.

Supporting information

S1 Fig. Effects of BET inhibitor on HCC cell line HepG2. HepG2 cells were treated with JQ1, OTX015, or ABBV-075 at different concentrations for different durations. The viability of the HepG2 cells was determined using the WST-1 assay. The data represent three independent experiments. The values are the mean ± SD of triplicate experiments (\( p < 0.05 \) and \( ** p < 0.01 \)). (TIF)

S2 Fig. Gene set enrichment analysis (GSEA) of DEmRNAs in each module. The degree of enrichment of total DEmRNAs (A), DEmRNAs in Module 1 (B), and Module 2 (C) represents a normalized enrichment score (NES). The right panel of each graph shows the GSEA enrichment plot. (TIF)

S3 Fig. Functional annotation of commonly expressed lncRNAs treated with three BET inhibitors. GREAT computes all GO term enrichment for genes upstream and downstream of
TSS based on the genomic regions of DElncRNAs commonly expressed in the three BET inhibitor treatments. (A) The number of associated genes in cis-regulatory genomic regions. (B) Distance (kb) to the nearest transcriptional start site (TSS) of commonly expressed DElncRNAs in the three BET inhibitor treatments. (C) Absolute distance to DElncRNAs and TSS sites. (D) Functional annotation analysis of DElncRNAs using GREAT shows for the top 5 GO terms in BP (top panel), CC (middle panel), and MF (bottom panel).

**S4 Fig. Functional annotation and pathway enrichment analysis of DEmRNAs of each BET inhibitor treatment.** HepG2 cells were treated with JQ1 (A), OTX-015 (B), and ABBV-075 (C). The top 5 enriched GO terms (top panel), KEGG pathways (middle panel), and GSEA (bottom panel) show the results of functional analysis of up- and down-regulated DEmRNAs. Different colors represent up- (red) and downregulated (blue) DEmRNAs.

**S5 Fig. Verification of DEmRNAs in Human HCC cell line Huh7.** Expression levels of DEmRNAs in Huh7 cells were analyzed by qRT-PCR and normalized to GAPDH transcript levels. The data represent three independent experiments. The values are the mean ± SD of triplicate experiments (**p < 0.01).**

**S6 Fig. Verification of DElncRNAs in Human HCC cell line Huh7.** Expression levels of DElncRNAs in Huh7 cells were analyzed by qRT-PCR and normalized to U6 transcript levels. The data represent three independent experiments. The values are the mean ± SD of triplicate experiments (**p < 0.01).**

**S1 Table. List of primers for qRT-PCR.**

**S2 Table. Top 50 significant up- and downregulated DEmRNAs in JQ1-treated HepG2 cells.**

**S3 Table. Top 50 significant up- and downregulated DElncRNAs in JQ1-treated HepG2 cells.**

**S4 Table. Top 50 significant up- and downregulated DEmRNAs in OTX015-treated HepG2 cells.**

**S5 Table. Top 50 significant up- and downregulated DElncRNAs in OTX015-treated HepG2 cells.**

**S6 Table. Top 50 significant up- and downregulated DEmRNAs in ABBV-075-treated HepG2 cells.**

**S7 Table. Top 50 significant up- and downregulated DElncRNAs in ABBV-075-treated HepG2 cells.**
S8 Table. Top 50 significant up- and downregulated DEmRNAs in BET inhibitor-treated HepG2 cells in common.
(DOCX)

S9 Table. Top 50 significant up- and downregulated DElncRNAs in BET inhibitor-treated HepG2 cells in common.
(DOCX)

S10 Table. Pearson correlation coefficients (PCC) value of DElncRNA-DEmRNA pairs in Module 1.
(XLSX)

S11 Table. Pearson correlation coefficients (PCC) value of DElncRNA-DEmRNA pairs in Module 2.
(XLSX)

Author Contributions
Conceptualization: Mina Baek, Kyoung Hwa Jung, Young Gyu Chai.

Data curation: Jin Choul Chai, Hae In Choi, Bert Binas, Young Seek Lee, Kyoung Hwa Jung.

Funding acquisition: Bert Binas, Young Seek Lee, Kyoung Hwa Jung, Young Gyu Chai.

Investigation: Hae In Choi, Eunyoung Yoo.

Methodology: Jin Choul Chai.

Project administration: Mina Baek.

Software: Jin Choul Chai.

Supervision: Young Gyu Chai.

Validation: Hae In Choi, Eunyoung Yoo.

Writing – original draft: Mina Baek.

Writing – review & editing: Mina Baek, Bert Binas.

References
1. Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019; 380(15):1450–62. Epub 2019/04/11. https://doi.org/10.1056/NEJMra1713263 PMID: 30970190.

2. Rebouissou S, Nault JC. Advances in molecular classification and precision oncology in hepatocellular carcinoma. J Hepatol. 2020; 72(2):215–29. Epub 2020/01/20. https://doi.org/10.1016/j.jhep.2019.08.017 PMID: 31954487.

3. Dhanasekaran R, Nault JC, Roberts LR, Zucman-Rossi J. Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. Gastroenterology. 2019; 156(2):492–509. Epub 2018/11/08. https://doi.org/10.1053/j.gastro.2018.11.001 PMID: 30404026; PubMed Central PMCID: PMC6340723.

4. Toh TB, Lim JJ, Chow EK. Epigenetics of hepatocellular carcinoma. Clin Transl Med. 2019; 8(1):13. Epub 2019/05/06. https://doi.org/10.1186/s40169-019-0230-0 PMID: 31056726; PubMed Central PMCID: PMC6500786.

5. Zaware N, Zhou MM. Bromodomain biology and drug discovery. Nat Struct Mol Biol. 2019; 26(10):870–9. Epub 2019/10/05. https://doi.org/10.1038/s41594-019-0309-8 PMID: 31582847; PubMed Central PMCID: PMC6984398.

6. Stathis A, Bertoni F. BET Proteins as Targets for Anticancer Treatment. Cancer Discov. 2018; 8(1):24–36. Epub 2017/12/22. https://doi.org/10.1158/2159-8290.CD-17-0605 PMID: 29263030.
1. Doroshow DB, Eder JP, LoRusso PM. BET inhibitors: a novel epigenetic approach. Ann Oncol. 2017; 28(8):1776–87. Epub 2017/08/26. https://doi.org/10.1093/annonc/mdx157 PMID: 28838216.

2. Alqahtani A, Choucair K, Ashraf M, Hammouda DM, Alloghbi A, Khan T, et al. Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy. Future Sci OA. 2019; 5(3):FSO372. Epub 2019/03/25. https://doi.org/10.4155/fsoa-2018-0115 PMID: 30906568; PubMed Central PMID: PMC6426170.

3. Hong SH, Eun JW, Choi SK, Shen Q, Choi WS, Han JW, et al. Epigenetic reader BRD4 inhibition as a therapeutic strategy to suppress EZF2-cell cycle regulation circuit in liver cancer. Oncotarget. 2016; 7(22):32628–40. Epub 2016/04/16. https://doi.org/10.18632/oncotarget.8701 PMID: 27081696; PubMed Central PMID: PMC5078039.

4. Yang Y, Deng X, Chen X, Chen S, Song L, Meng M, et al. Landscape of active enhancers developed de novo in cirrhosis and conserved in hepatocellular carcinoma. Am J Cancer Res. 2020; 10(10):3157–78. Epub 2020/11/10. PMID: 33163263; PubMed Central PMID: PMC7642653.

5. Yin Y, Sun M, Zhan X, Wu C, Geng P, Sun X, et al. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncopgenic MYC. J Exp Clin Cancer Res. 2019; 38(1):83. Epub 2019/02/17. https://doi.org/10.1186/s13046-019-1082-6 PMID: 30770740; PubMed Central PMID: PMC6377788.

6. Amorim S, Thathis A, Gleson M, lyengar S, Magarotto V, Leleu X, et al. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. Lancet Haematol. 2016; 3(4):e196–204. Epub 2016/04/12. https://doi.org/10.1016/S2352-3026(16)00021-1 PMID: 27063978.

7. Statthis A, Zucca E, Bekradda M, Gomez-Roca C, Delord JP, de La Motte Rouge T, et al. Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628. Cancer Discov. 2016; 6(5):492–500. Epub 2016/03/16. https://doi.org/10.1158/2159-8290.CD-15-1335 PMID: 26976114; PubMed Central PMID: PMC4954801.

8. Lewin J, Soria JC, Thathis A, Delord JP, Peters S, Awada A, et al. Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors. J Clin Oncol. 2018; 36(30):3007–14. Epub 2018/05/08. https://doi.org/10.1200/JCO.2018.78.2292 PMID: 29733771.

9. Piha-Paul SA, Sachdev JC, Barve M, LoRusso P, Szumewlitz R, Patel SP, et al. First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors. Cancer Res. 2019; 79(21):6309–19. Epub 2019/08/20. https://doi.org/10.1158/1078-0432.CCR-19-0578 PMID: 31420359.

10. Palazzo AF, Koonin EV. Functional Long Non-coding RNAs Evolve from Junk Transcripts. Cell. 2020; 183(5):1151–61. Epub 2020/10/18. https://doi.org/10.1016/j.cell.2020.09.047 PMID: 33068526.

11. Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021; 22(2):96–118. Epub 2020/12/24. https://doi.org/10.1038/s41580-020-00315-9 PMID: 33353982; PubMed Central PMID: PMC7754182.

12. Lin C, Yang L. Long Noncoding RNA in Cancer: Wiring Signaling Circuity. Trends Cell Biol. 2018; 28(4):287–301. Epub 2017/12/25. https://doi.org/10.1016/j.tcb.2017.11.008 PMID: 29274663; PubMed Central PMID: PMC5869122.

13. Winkle M, El-Daly SM, Fabbri M, Calin GA. Noncoding RNA therapeutics—challenges and potential solutions. Nat Rev Drug Discov. 2021; 20(8):492–500. Epub 2021/06/24. https://doi.org/10.1038/s41573-021-00219-z PMID: 34157369; PubMed Central PMID: PMC812082.

14. iaccarino I, Klapper W. LncRNA as Cancer Biomarkers. Methods Mol Biol. 2021; 2348:27–41. Epub 2021/06/24. https://doi.org/10.1007/978-1-0716-1581-2_2 PMID: 34160797.

15. Liu SJ, Dang HX, Lim DA, Feng FY, Maher CA. Long noncoding RNAs in cancer metastasis. Nat Rev Cancer. 2021; 21(7):446–60. Epub 2021/05/07. https://doi.org/10.1038/s41564-021-00353-1 PMID: 33953369; PubMed Central PMID: PMC8288800.

16. Panzitt K, Tschematsch MM, Guelle C, Moustafa T, Stradner M, Strohmaier HM, et al. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology. 2007; 132(1):330 –42. Epub 2007/01/24. https://doi.org/10.1053/j.gastro.2006.08.026 PMID: 17241883.

17. Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ, Tao QF, et al. A long noncoding RNA activated by TGF-beta promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell. 2014; 25(5):666–81. Epub 2014/04/29. https://doi.org/10.1016/j.ccr.2014.03.010 PMID: 24768205.

18. Quagliata L, Matter MS, Piecuchigo S, Arabi L, Ruiz C, Procino A, et al. Long noncoding RNA HOTTIP/ HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. Hepatology. 2014; 59(3):911–23. Epub 2013/10/12. https://doi.org/10.1002/hep.26740 PMID: 24114970; PubMed Central PMID: PMC3943759.
25. Fu WM, Zhu X, Wang WM, Lu YM, Hu BG, Wang H, et al. Hotair mediates hepatocarcinogenesis through suppressing miRNA-218 expression and activating P14 and P16 signaling. J Hepatol. 2015; 63 (4):886–95. Epub 2015/05/31. https://doi.org/10.1016/j.jhep.2015.05.016 PMID: 26024833.

26. Li T, Xie J, Sheng C, Cheng D, Shi Y, Wu Z, et al. Ureapation of long noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in hepatocellular carcinoma. Oncogene. 2016; 35 (12):1575–84. Epub 2015/06/16. https://doi.org/10.1038/onc.2015.223 PMID: 26073087.

27. Lim LJ, WongSYS, Huang F, Lim S, Chong SS, Ooi LL, et al. Roles and Regulation of Long Noncoding RNAs in Hepatocellular Carcinoma. Cancer Res. 2019; 79(20):5131–9. Epub 2019/07/25. https://doi.org/10.1158/0008-5472.CAN-19-0255 PMID: 31337653.

28. Huang Z, Zhou JK, Peng Y, He W, Huang C. The role of long noncoding RNAs in hepatocellular carcinoma. Mol Cancer. 2020; 19(1):77. Epub 2020/04/17. https://doi.org/10.1186/s12943-020-01188-4 PMID: 32295598; PubMed Central PMCID: PMC7161154.

29. Jung KH, Das A, Chai JC, Kim SH, Morya N, Park KS, et al. RNA sequencing reveals distinct mechanisms underlying BET inhibitor JQ1-mediated modulation of the LPS-induced activation of BV-2 microglial cells. J Neuroinflammation. 2015; 12:36. Epub 2015/04/19. https://doi.org/10.1186/s12974-015-0260-5 PMID: 25890327; PubMed Central PMCID: PMC4359438.

30. Baek M, Yoo E, Choi HI, An GY, Chai JC, LeeYS, et al. The BET inhibitor attenuates the inflammatory response and cell migration in human microglial HMC3 cell line. Sci Rep. 2021; 11(1):8828. Epub 2021/04/25. https://doi.org/10.1038/s41598-021-87828-1 PMID: 33893325; PubMed Central PMCID: PMC8065145.

31. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014; 30(15):2114–20. Epub 2014/04/04. https://doi.org/10.1093/bioinformatics/btu170 PMID: 24695404; PubMed Central PMCID: PMC4103590.

32. Dobin A, Davis CA, Schlesinger F, Denkow J, Zalesski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013; 29(1):15–21. Epub 2012/10/30. https://doi.org/10.1093/bioinformatics/bts635 PMID: 23104886; PubMed Central PMCID: PMC3530905.

33. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. Epub 2014/12/18. https://doi.org/10.1186/s13059-014-0550-8 PMID: 25516261; PubMed Central PMCID: PMC4302049.

34. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44–57. Epub 2009/01/10. https://doi.org/10.1038/nprot.2008.211 PMID: 19131956.

35. Bu D, Luo H, Hua P, Wang Z, Zhang S, He Z, et al. KOBAS-i: intelligent prioritization and exploratory visualization of biological functions for gene enrichment analysis. Nucleic Acids Res. 2021; 49(W1):W317–W25. Epub 2021/06/05. https://doi.org/10.1093/nar/gkab447 PMID: 34086934; PubMed Central PMCID: PMC8265193.

36. McLean CY, Brister D, Miller M, Clarke SL, Schaer BT, Lowe CB, et al. GREAT improves functional interpretation of cis-regulatory regions. Nat Biotechnol. 2010; 28(5):495–501. Epub 2010/05/04. https://doi.org/10.1038/nbt.1630 PMID: 20436461; PubMed Central PMCID: PMC4840234.

37. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545–50. Epub 2005/10/04. https://doi.org/10.1073/pnas.0506580102 PMID: 16199517; PubMed Central PMCID: PMC1298996.

38. Kramer A, Green J, Pollard J Jr., Tugendreich S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics. 2014; 30(4):523–30. Epub 2014/02/25. https://doi.org/10.1093/bioinformatics/bts635 PMID: 23104886; PubMed Central PMCID: PMC8265193.

39. McLean CY, Brister D, Miller M, Clarke SL, Schaer BT, Lowe CB, et al. GREAT improves functional interpretation of cis-regulatory regions. Nat Biotechnol. 2010; 28(5):495–501. Epub 2010/05/04. https://doi.org/10.1038/nbt.1630 PMID: 20436461; PubMed Central PMCID: PMC4840234.

40. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545–50. Epub 2005/10/04. https://doi.org/10.1073/pnas.0506580102 PMID: 16199517; PubMed Central PMCID: PMC1298996.

41. Kramer A, Green J, Pollard J Jr., Tugendreich S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics. 2014; 30(4):523–30. Epub 2014/02/25. https://doi.org/10.1093/bioinformatics/bts635 PMID: 23104886; PubMed Central PMCID: PMC8265193.

42. Chang KH, Sanchez-Aguilera A, Shen S, Sengupta A, Madhu MN, Ficker AM, et al. Vav3 collaborates with p190-BCR-ABL in lymphoid progenitor leukemogenesis, proliferation, and survival. Blood. 2012; 120(4):800–11. Epub 2012/06/14. https://doi.org/10.1182/blood-2011-06-361709 PMID: 22692505.
43. Lam LT, Lin X, Fairey EJ, Yang Z, Huang X, Wilcox DM, et al. Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors. Mol Cancer Ther. 2017; 16(8):1511–20. Epub 2017/05/05. https://doi.org/10.1158/1535-7163.MCT-16-0459 PMID: 28468776.

44. Bui MH, Lin X, Albert DH, Li L, Lam LT, Fairey EJ, et al. Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies. Cancer Res. 2017; 77(11):2976–89. Epub 2017/04/19. https://doi.org/10.1158/0008-5472.CAN-16-1793 PMID: 28416490.

45. Brockmoller SF, Bucher E, Muller BM, Budczies J, Hilvo M, Griffin JL, et al. Integration of metabolomics and expression of glycerol-3-phosphate acyltransferase (GPAM) in breast cancer-link to patient survival, hormone receptor status, and metabolic profiling. J Proteome Res. 2012; 11(2):850–60. Epub 2011/11/11. https://doi.org/10.1021/pr200685r PMID: 22070544.

46. Marchan R, Buttner B, Lambert J, Edlund K, Glaeser I, Blaszkewicz M, et al. Glycerol-3-phosphate Acyltransferase 1 Promotes Tumor Cell Migration and Poor Survival in Ovarian Carcinoma. Cancer Res. 2017; 77(17):4589–601. Epub 2017/06/28. https://doi.org/10.1158/0008-5472.CAN-16-2065 PMID: 28876252.

47. Rusu P, Shao C, Neuerburg A, Acikgoz AA, Wu Y, Zou P, et al. GPD1 Specifically Marks Dormant Glioma Stem Cells with a Distinct Metabolic Profile. Cell Stem Cell. 2019; 25(2):241–57 e8. Epub 2019/07/16. https://doi.org/10.1016/j.stem.2019.06.004 PMID: 31303549.

48. Chen D, Jin C, Dong X, Wen J, Xia E, Wang Q, et al. Pan-cancer analysis of the prognostic and immunological role of PSMB8. Sci Rep. 2021; 11(1):20492. Epub 2021/10/16. https://doi.org/10.1038/s41598-021-99724-9 PMID: 34650125; PubMed Central PMCID: PMC8516870.

49. Chang HH, Cheng YC, Tsai WC, Chen Y. PSMB8 inhibition decreases tumor angiogenesis in glioblastoma through vascular endothelial growth factor A reduction. Cancer Sci. 2020; 111(1):4142–53. Epub 2020/08/21. https://doi.org/10.1111/cas.14625 PMID: 32816328; PubMed Central PMCID: PMC7648028.

50. Lin X, Huang X, Uziel T, Hessler P, Albert DH, Roberts-Rapp LA, et al. HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues. Mol Cancer Ther. 2017; 16(2):88–96. Epub 2016/12/03. https://doi.org/10.1158/1535-7163.MCT-16-0475 PMID: 27903752.

51. Funato Y, Yamazaki D, Mizukami S, Du L, Kikuchi K, Miki H. Membrane protein CNNM4-dependent Mg2+ efflux suppresses tumor progression. J Clin Invest. 2014; 124(12):5398–410. Epub 2014/10/28. https://doi.org/10.1172/JCI76614 PMID: 25347473; PubMed Central PMCID: PMC4348944.

52. Gui D, Dong Z, Peng W, Jiang W, Huang G, Liu G, et al. Ubiquitin-specific peptidase 53 inhibits the occurrence and development of clear cell renal cell carcinoma through NF-kappaB pathway inactivation. Cancer Med. 2021; 10(11):3674–88. Epub 2021/05/12. https://doi.org/10.1002/cam4.3911 PMID: 33937390; PubMed Central PMCID: PMC8179486.

53. Zhao X, Wu X, Wang H, Yu H, Wang J. USP53 promotes apoptosis and inhibits glycolysis in lung adenocarcinoma through FKBPS1-AKT1 signaling. Mol Carcinog. 2020; 59(6):1000–11. Epub 2020/06/09. https://doi.org/10.1002/mc.23230 PMID: 32511815.

54. Wong CM, Tsang FH. Ng IO. Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications. Nat Rev Gastroenterol Hepatol. 2018; 15(3):137–51. Epub 2018/01/11. https://doi.org/10.1038/nrgastro.2017.169 PMID: 29317776.

55. Ding CH, Yin C, Chen SJ, Wen LZ, Ding K, Lei SJ, et al. The HNF1alpha-regulated IncRNA HNF1A-AS1 reverses the malignancy of hepatocellular carcinoma by enhancing the phosphatase activity of SHP-1. Mol Cancer. 2018; 17(1):63. Epub 2018/02/23. https://doi.org/10.1002/mc.23230 PMID: 29466992; PubMed Central PMCID: PMC5822613.

56. Li YH, Huang GM, pang W, Zang HL. LncRNA HAGLR exacerbates hepatocellular carcinoma through negatively regulating miR-6785-5p. Eur Rev Med Pharmacol Sci. 2020; 24(18):9353–60. Epub 2020/10/06. https://doi.org/10.26355/eurrev_202009_23018 PMID: 33015776.

57. Pu J, Tan C, Shao Z, Wu X, Zhang Y, Xu Z, et al. Long Noncoding RNA PART1 Promotes Hepatocellular Carcinoma Progression via Targeting miR-590-3p/HMBG2 Axis. Onco Targets Ther. 2020; 13:9203–11. Epub 2020/09/29. https://doi.org/10.2147/OTT.S259962 PMID: 32982307; PubMed Central PMCID: PMC7502387.

58. Chen Z, Xiang L, Hu Z, Ou H, Liu X, Yu L, et al. Epigenetically silenced Lnc00261 contributes to the metastasis of hepatocellular carcinoma via inducing the deficiency of FOXA2 transcription. Am J Cancer Res. 2021; 11(1):277–96. Epub 2021/02/02. PMID: 33520374; PubMed Central PMCID: PMC7840721.

59. Deng P, Li K, Gu F, Zhang T, Zhao W, Sun M, et al. LINC00242/miR-1-3p/G6PD axis regulates WARBurg effect and affects gastric cancer proliferation and apoptosis. Mol Med. 2021; 27(1):9. Epub 2021/
60. Wu J, Gao L, Zhou H, Zhou X, Lu X, Mao Z. LINC02535 promotes cell growth in poorly differentiated gastric cancer. J Clin Lab Anal. 2021; 35(8):e23877. Epub 2021/06/15. https://doi.org/10.1002/jcla.23877 PMID: 34125981; PubMed Central PMCID: PMC8373362.

61. Lu Y, Wang W, Liu Z, Ma J, Zhou X, Fu W. Long non-coding RNA profile study identifies a metabolism-related signature for colorectal cancer. Mol Med. 2021; 27(1):83. Epub 2021/08/05. https://doi.org/10.1186/s10020-021-00343-x PMID: 34344319; PubMed Central PMCID: PMC8336290.

62. Hadjicharalambous MR, Roux BT, Feghali-Bostwick CA, Murray LA, Clarke DL, Lindsay MA. Long Non-coding RNAs Are Central Regulators of the IL-1beta-Induced Inflammatory Response in Normal and Idiopathic Pulmonary Lung Fibroblasts. Front Immunol. 2018; 9:2906. Epub 2019/01/09. https://doi.org/10.3389/fimmu.2018.02906 PMID: 30619270; PubMed Central PMCID: PMC6299252.

63. Wang M, Bu X, Luan G, Lin L, Wang Y, Jin J, et al. Distinct type 2-high inflammation associated molecular signatures of chronic rhinosinusitis with nasal polyps with comorbid asthma. Clin Transl Allergy. 2020; 10:26. Epub 2020/07/09. https://doi.org/10.1186/s13601-020-00332-z PMID: 32637070; PubMed Central PMCID: PMC7333405.

64. Li N, Zhang H, Hu K, Chu J. A novel long non-coding RNA-based prognostic signature for renal cell carcinoma patients with stage IV and histological grade G4. Bioengineered. 2021; 12(1):6275–85. Epub 2021/09/10. https://doi.org/10.1080/21655979.2021.1971022 PMID: 34499010.

65. Gao X, Liu Q, Chen X, Chen S, Yang J, Liu Q, et al. Screening of tumor grade-related mRNAs and lncRNAs for Esophageal Squamous Cell Carcinoma. J Clin Lab Anal. 2021; 35(6):e23797. Epub 2021/05/08. https://doi.org/10.1002/jcla.23797 PMID: 33960436; PubMed Central PMCID: PMC8183932.

66. Cochran AG, Conery AR, Sims RJ, 3rd. Bromodomains: a new target class for drug development. Nat Rev Drug Discov. 2019; 18(8):609–28. Epub 2019/07/06. https://doi.org/10.1038/s41573-019-0030-7 PMID: 31273347.

67. Gilan O, Rioja I, Knezevic K, Bell MJ, Yeung MM, Harker NR, et al. Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. Science. 2020; 368(6489):387–94. Epub 2020/03/21. https://doi.org/10.1126/science.aaz8455 PMID: 32193360; PubMed Central PMCID: PMC7610820.

68. Faivre EJ, McDaniel KF, Albert DH, Mantena SR, Plotnik JP, Wilcox D, et al. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer. Nature. 2020; 578(7794):306–10. Epub 2020/01/24. https://doi.org/10.1038/s41586-020-1930-8 PMID: 31969702.